• English
  • Español
  • Facebook
  • RSS
  • Twitter

Therapeutics Initiative

Independent Healthcare Evidence

  • TI
  • About Us
    • Oversight Committee
    • Executive Committee
    • Working Groups
      • Drug Assessment
      • Education
      • Therapeutics Letter
      • PharmacoEpidemiology
      • Quality Prescribing
      • Cochrane Hypertension
    • Members
    • TI Surveys
    • Questions & Answers
  • Therapeutics Letter
  • Our Evidence Reviews
  • Get Involved
  • Continuing Education
  • Contact Us
Home > Archives for COPD

[109] Inhaled long acting β2 agonists for COPD

February 6, 2018 Therapeutics Letter Leave a Comment

Download
Share

In Therapeutics Letter #1021 we reviewed the inhaled long acting β2 agonist (LABA) indacaterol for chronic obstructive pulmonary disease (COPD). We concluded “There are no proven clinically meaningful benefits in terms of reduction in mortality or total serious adverse events…” for this indication based on 12 trials in 6,947 patients. In this Letter we report systematic reviews of 3 other inhaled … [Read more...]

[102] Indacaterol for chronic obstructive pulmonary disease

January 26, 2017 Therapeutics Letter Leave a Comment

Download
Share

Chronic obstructive pulmonary disease (COPD) is an inflammatory condition characterized by irreversible airflow obstruction. It is caused by exposure to noxious particles or gases, with exposure to cigarette smoke the most common cause. Several classes of drugs can be prescribed: short and long-acting beta2 (β2) agonist, short and long-acting antimuscarinic, inhaled corticosteroids and … [Read more...]

  • About Us
    • Oversight Committee
    • Questions & Answers
    • Executive Committee
    • Working Groups
      • Drug Assessment
      • Education
      • Therapeutics Letter
      • PharmacoEpidemiology
      • Quality Prescribing
      • Cochrane Hypertension
    • Members
    • TI Surveys
  • Therapeutics Letter
  • Our Evidence Reviews
  • Get Involved
  • Continuing Education
    • Best Evidence
  • Contact Us
  • Terms & Policies
    • Legal Information & Terms of Use
    • Privacy Policy
    • Acceptable Use Policy

Categories

  • News (111)
  • Therapeutics Letter (123)
  • Drug Assessments (36)
  • PharmacoEpidemiology (60)
  • Podcasts & Videos (18)

Recent Seminars

Dr. Joanna Moncrieff: Drug treatment for bipolar disorder and psychosis

Share

Methods Speaker Series 2019

Share

Twenty-Five Pearls from 25 years

Share

Therapeutics Initiative

Our mission is to provide physicians, pharmacists, allied health professionals, and the public with up-to-date, independent, evidence-based, practical information on healthcare interventions. Read more Donate

Contact

2176 Health Sciences Mall
Vancouver, BC, Canada V6T 1Z3

Office: +1 604-822-0700
Fax: +1 604-822-0701

UBC logoISDB logo

Subscribe

Subscribe to receive email notifications about the Therapeutics Letter, upcoming educational events, and recent publications from the TI.

© 1994 - 2019 Therapeutics Initiative · Terms & Policies · TM